| Name: | Montelukast Sulphoxide Impurity |
| Catalogue No. | VL510006 |
| CAS No. | N/A |
| Molecular Formula | C35H36ClNO4S |
| Molecular Weight | 602.18 |
| Status | In-stock |
| IUPAC Name | 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfinylmethyl]cyclopropyl]acetic Acid |
| Synonyms | Montelukast USP Related Compound C/ Montelukast Sulfoxid/Montelukast EP Impurity C/Montelukast Related Compound A |
| Appearance | Off white powder |
| Description | Montelukast Sulphoxide Impurity (CAS No: 909849-96-3) is an impurity present in montelukast which is an effective cysteinyl leukotriene (cysLT) receptor antagonist that protected against mouse BPD induced by hyperoxia thereby inhibiting inflammation, oxidative stress, and lung cell apoptosis. |
| References | Barnabas, K. Samuel, et al. “A Novel Stability-Indicating Method for Determination of Related Substances of Montelukast Sodium in a Pharmaceutical Dosage Form Using RP-HPLC.” Chromatographia, vol. 84, no. 7, June 2021, pp. 645–62, https://doi.org/10.1007/s10337-021-04045-8. Chen, Xin, et al. “Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms.” Medical Science Monitor, vol. 25, Mar. 2019, pp. 1886–93, https://doi.org/10.12659/msm.912774. |
